Kronos Bio, INC 10-Q quarterly reports

Kronos Bio reports Q1 2025 financial results, highlighted by a net loss of $8.364 million, and announces a definitive merger agreement with Concentra Biosciences.

Kronos Bio discontinues its lead clinical program, istisociclib, and initiates a strategic review process to maximize stockholder value.

Kronos Bio's second quarter 2024 results show a net loss of $16.2 million, reflecting ongoing restructuring efforts and continued investment in research and development.

Kronos Bio's first quarter 2024 results reflect a net loss of $30 million, impacted by restructuring costs and asset impairments, despite a revenue increase from a collaboration agreement.